The company
Royalty Pharma plc - Class A
RPRX · Nasdaq
RPRX stood above a rising 150-day average in 52 of the last 52 weekly readings, every one of them. It is 12.8% above that average now. Pharmaceuticals: 32% of its 74 stocks in an uptrend (−9 points in four weeks); Health Care: 28% (−9 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 52 in a row
- Industry in uptrend
- 32% -10 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $155.1M
- Officials’ trades on record
- 3
- Institutions holding
- 605 (+54)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 52 of 52 weeks.
Pharmaceuticals: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
3 disclosed lines: House 0, Senate 0, executive 3; 2 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 7 Apr 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 19 Feb 2026filed 14 May 2026 |
| Christopher Landau Executive branch: Office of Government EthicsDepartment of State | sold | $100k–$250k | 28 Apr 2025filed 16 Jul 2025 |
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Marshall UristEVP, Research & Investments | sold | 4,126at $57.10 | 5 Oct 2026filed 5 Oct 2026 |
| Marshall UristEVP, Research & Investments | sold | 4,126at $57.88 | 28 Sep 2026filed 30 Sep 2026 |
| Christopher HiteEVP & Chairman, Partnering | sold | 96,073at $58.51 | 22 Sep 2026filed 24 Sep 2026 |
| Christopher HiteEVP & Chairman, Partnering | sold | 3,927at $58.93 | 22 Sep 2026filed 24 Sep 2026 |
| Christopher HiteEVP & Chairman, Partnering | sold | 100,000at $59.97 | 18 Aug 2026filed 19 Aug 2026 |
| Terrance P. CoyneEVP & CFO | sold | 9,230at $58.59 | 13 Aug 2026filed 17 Aug 2026 |
| Terrance P. CoyneEVP & CFO | sold | 1,772at $59.14 | 13 Aug 2026filed 17 Aug 2026 |
| Marshall UristEVP, Research & Investments | sold | 9,099at $55.88 | 1 Jul 2026filed 2 Jul 2026 |
| Christopher HiteEVP & Chairman, Partnering | sold | 97,446at $56.50 | 30 Jun 2026filed 2 Jul 2026 |
| Christopher HiteEVP & Chairman, Partnering | sold | 2,554at $57.10 | 30 Jun 2026filed 2 Jul 2026 |
| Christopher HiteEVP & Chairman, Partnering | sold | 29,400at $56.44 | 30 Jun 2026filed 2 Jul 2026 |
| Christopher HiteEVP & Chairman, Partnering | sold | 600at $57.09 | 30 Jun 2026filed 2 Jul 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| MORGAN STANLEYreduced · filed 13 Aug 2026 | 42,931,597$2.4B | -640,036−1.5% |
| Capital International Investorsadded · filed 12 Aug 2026 | 35,273,770$2.0B | +268,034+0.8% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 27,832,977$1.6B | +1,925,232+7.4% |
| FMR LLCreduced · filed 13 Aug 2026 | 24,513,814$1.4B | -638,428−2.5% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 12,338,229$691.8M | +1,348,378+12.3% |
| Swedbank ABreduced · filed 15 Jul 2026 | 10,726,608$601.4M | -860,085−7.4% |
| BAILLIE GIFFORD & COreduced · filed 6 Aug 2026 | 10,015,578$561.6M | -6,140,099−38.0% |
| Capital World Investorsadded · filed 12 Aug 2026 | 9,517,337$533.6M | +1,480,623+18.4% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 8,058,048$450.6M | +188,416+2.4% |
| Caledonia (Private) Investments Pty Ltdreduced · filed 14 Aug 2026 | 5,775,851$323.9M | -1,392,548−19.4% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.